LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
- Resource Type
- article
- Source
- Lupus Science and Medicine, Vol 10, Iss Suppl 1 (2023)
- Subject
Immunologic diseases. Allergy RC581-607 - Language
- English
- ISSN
- 2053-8790